

Date and Time: 6th September 2013 10:00-16:00

Minutes: Confirmed

Multiple Sclerosis GDG Meeting 9

Place: Boardroom, National Clinical Guideline Centre, 180 Great Portland Street,
 London, W1W 5QZ

Present: GDG

1. Paul Cooper	PC
2. Jeremy Chataway	JC
3. Peter Brex	PB
4. Wendy Hendrie	WH
5. Susan Hourihan	SH
6. Noreen Barker	NB
7. Richard Warner	RW
8. Aleks de Gromoboy	ADG
9. Ann Hodgson	AH
10. Emma Rowe	ER
11. David Kernick	DK
12. Pamela Bostock	PBo

NCGC Technical team

13. Sharon Swain	SS
14. Mark Perry	MP
15. Amy Kelsey	AK
16. Sophia Winterbourne	SW
17. Krishna Chinthapalli	KC
18. Norma O'Flynn	NOF

NICE:

1. Caroline Keir	CK
------------------	----

Apologies

1. Mark Perry	MP
---------------	----

Notes

1. The Chair welcomed the group to the Multiple Sclerosis Guideline Development Group (GDG) meeting 9. Apologies were received from Mark Perry.
2. The Chair asked the GDG to declare any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests.

NB declared the following non-personal pecuniary interests: she is due to attend the MS Trust conference in November 2013 where conference fees and accommodation are funded via the risk sharing scheme; she is also due to attend a neuro-examination course sponsored by Teva in November 2013.

RW declared the following personal non-pecuniary interests: he will be attending ECTRIMS in October 2013 sponsored by Novartis.

SH declared the following personal non-pecuniary interest: she is attending the MS Trust conference in November 2013 where she will be presenting. Food and accommodation are provided by the MS Trust.

JC declared the following personal pecuniary interests: he is attending ECTRIMS in October 2013, sponsored by Teva; he is attending the MS Trust conference in November 2013; he gave a lecture for Biogen in July 2013.

3. The Chair introduced Sharon Swain, NCGC Senior Research Fellow, who presented the clinical evidence review of the use of structural assessments compared with non-structured assessments and whether or not they improve patient and carer outcomes for people with MS. The GDG discussed the evidence presented. The Chair thanked SS for her presentation.
4. The Chair introduced Sophia Winterbourne, NCGC Health Economist, who presented the health economic evidence review of the use of structural assessments compared with non-structured assessments and whether or not they improve patient and carer outcomes for people with MS. The GDG discussed the evidence presented. The Chair thanked SW for her presentation.
5. SW then presented a health economics update on the Oscillopsia review to the GDG. The GDG discussed the update and amended the draft recommendation.
6. SW then presented a health economics update on the Rehabilitation Settings review to the GDG. The GDG discussed the update and made no changes to the draft recommendation. The Chair thanked SW for her presentations.
7. SS then presented the clinical evidence review of the pharmacological treatment of fatigue for people with MS. The GDG discussed the evidence presented. The Chair thanked SS for her presentation.
8. SW then presented the health economic evidence review of the pharmacological treatment of fatigue for people with MS. The GDG discussed the evidence presented. The Chair thanked SW for her presentation.
9. The Chair introduced Norma O'Flynn, NCGC Clinical Director and guideline lead, who presented a draft algorithm to the GDG. The Chair thanked NOF for her presentation.

Notes

10. There was no AOB. The Chair closed the meeting and thanked everyone for attending.

Date, time and venue of the next meeting

11. 25th October 2013, 10:00-16:00, Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ